A detailed history of Captrust Financial Advisors transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 5,478 shares of ITCI stock, worth $484,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,478
Previous 6,717 18.45%
Holding current value
$484,748
Previous $464,000 19.18%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$64.76 - $79.84 $80,237 - $98,921
-1,239 Reduced 18.45%
5,478 $375,000
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $850,327 - $999,336
-13,210 Reduced 66.29%
6,717 $464,000
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $315,084 - $500,451
-6,795 Reduced 25.43%
19,927 $1.43 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $413,698 - $509,082
7,942 Added 42.29%
26,722 $1.39 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $714,810 - $868,703
13,075 Added 229.18%
18,780 $1.19 Million
Q1 2023

May 15, 2023

SELL
$43.8 - $56.99 $2,321 - $3,020
-53 Reduced 0.92%
5,705 $308,000
Q4 2022

Feb 15, 2023

BUY
$44.07 - $54.45 $253,755 - $313,523
5,758 New
5,758 $304,000
Q2 2022

Aug 23, 2022

SELL
$43.0 - $65.64 $2,365 - $3,610
-55 Reduced 5.29%
984 $56,000
Q2 2022

Aug 16, 2022

BUY
$43.0 - $65.64 $1,462 - $2,231
34 Added 3.38%
1,039 $59,000
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $3,835 - $6,146
99 Added 10.93%
1,005 $61,000
Q4 2021

Feb 14, 2022

BUY
$35.2 - $53.42 $8,131 - $12,340
231 Added 34.22%
906 $47,000
Q3 2021

Nov 16, 2021

BUY
$28.72 - $42.49 $2,584 - $3,824
90 Added 15.38%
675 $25,000
Q1 2021

May 17, 2021

BUY
$30.8 - $39.51 $8,778 - $11,260
285 Added 95.0%
585 $20,000
Q2 2020

Aug 14, 2020

BUY
$14.35 - $26.64 $4,305 - $7,992
300 New
300 $8,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.35B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.